



DOCKET NO. MUR-043-USA-PCT

J.E.G.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
K. Mori, et al.

Serial No.: 10/510,694

Art Unit: 3763

Filed: October 8, 2004

Examiner: To Be Assigned

For: Insulin-Administering Device

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants' counsel is in receipt of the PTO Filing Receipt for the above identified pending patent application, a copy of which is attached hereto. Upon verifying the accuracy of the data presented on the Filing Receipt it was noted that there are errors in the title for this invention which were introduced by the Patent Office. As evidenced by the attached copy of the Transmittal, Declaration and Power of Attorney, and first page of the original specification which contains the title, the title should be "**Insulin-Administering Device**" rather than "Insulin Administration Apparatus" written on the Filing Receipt.

It is respectfully requested that the Patent Office records be corrected to reflect the correct title and that the undersigned be provided with a corrected Filing Receipt.

Respectfully submitted,

TOWNSEND & BANTA

Donald E. Townsend, Jr.

Donald E. Townsend, Jr.
Reg. No. 43,198

Date: May 27, 2005

Customer No. 27955

TOWNSEND & BANTA
c/o PortfolioIP
P.O. Box 52050
Minneapolis, MN 55402
(202) 220-3124

CERTIFICATE OF MAILING

I hereby certify that this Request for Corrected Filing Receipt in Docket No. MUR-043-USA-PCT, Serial No. 10/510,694 filed October 8, 2004, was deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On May 27, 2005.

Donald E. Townsend, Jr.

Donald E. Townsend, Jr.



O P E JUN 01 2005
PATENT & TRADEMARK OFFICE

UNITED STATES PATENT AND TRADEMARK OFFICE

Page 1 of 2

80149-048US1

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/510,694	10/08/2004	3763	1038	MUR-043-USA-PCT	8	20	4

27955
TOWNSEND & BANTA
c/o PORTFOLIO IP
PO BOX 52050
MINNEAPOLIS, MN 55402

1/08/05 - IDS

CONFIRMATION NO. 4087

FILING RECEIPT



OC000000015670734

Date Mailed: 04/12/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Kenji Mori, Ibaraki, JAPAN;
Naruhito Higo, Ibaraki, JAPAN;
Seiji Tokumoto, Ibaraki, JAPAN;
Shuji Sato, Kanagawa, JAPAN;
Kenji Sugabayashi, Saitama, JAPAN;

Power of Attorney: The patent practitioners associated with Customer Number 27955.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/JP03/03992 03/28/2003


Foreign Applications

JAPAN 2002-105796 04/08/2002

Projected Publication Date: 07/14/2005

Non-Publication Request: No

Early Publication Request: No



Title

Insulin administration apparatus

Preliminary Class

604

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER MUR-043-USA-PCT
INTERNATIONAL APPLICATION NO. PCT/JP03/03992	INTERNATIONAL FILING DATE March 28, 2003	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)
		PRIORITY DATE CLAIMED April 8, 2002
TITLE OF INVENTION INSULIN-ADMINISTERING DEVICE		
APPLICANT(S) FOR DO/EO/US Kenji Mori, Naruhito Higo, Seiji Tokumoto, Shuji Sato, Kenji Sugibayashi		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input checked="" type="checkbox"/> The US has been elected (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. <input checked="" type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>		
Items 11 to 20 below concern document(s) or information included:		
<p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A preliminary amendment.</p> <p>14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A power of attorney and/or change of address letter.</p> <p>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).</p> <p>20. <input type="checkbox"/> Other items or information:</p>		

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

INSULIN-ADMINISTERING DEVICE

the specification of which is attached and/or was filed on as Application Serial No. and was amended on (if applicable)

international (PCT) application No. PCT/JP03/03992 filed Mar. 28, 2003 and as amended on (if any).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

COUNTRY	APPLICATION NUMBER	DATE OF FILING	PRIORITY CLAIMED UNDER 35 U.S.C. 119
JAPAN	2002-105796	April 8, 2002	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input checked="" type="checkbox"/> NO

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION NUMBER	DATE OF FILING	STATUS (Patented, Pending, Abandoned)

I hereby appoint the following attorneys to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: Law Offices of Townsend & Banta; Donald E. Townsend, Registration No. 22,069; ~~Registration No. 22,069~~ and Donald E. Townsend, Jr., Registration No. 43,198

Please address all correspondence to the Law Offices of Townsend & Banta, 601 Pennsylvania Avenue, N.W. Suite 900, South Building, Washington, D.C. 20004

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF SOLE OR FIRST INVENTOR MORI, Kenji	INVENTOR'S SIGNATURE 	DATE <u>Aug 11 04</u>
RESIDENCE c/o Tsukuba Laboratory of Hisamitsu Pharmaceutical Co., Inc., 25-11, Kannondai 1-chome, Tsukuba-shi, Ibaraki 305-0856 JAPAN	CITIZENSHIP	JAPANESE

POST OFFICE ADDRESS

FULL NAME OF SECOND JOINT INVENTOR, IF ANY HIGO, Naruhito	INVENTOR'S SIGNATURE 	DATE <u>Aug. 17, 2004</u>
RESIDENCE c/o Tsukuba Laboratory of Hisamitsu Pharmaceutical Co., Inc., 25-11, Kannondai 1-chome, Tsukuba-shi, Ibaraki 305-0856 JAPAN	CITIZENSHIP	JAPANESE

POST OFFICE ADDRESS

Listing of Inventors Continued on Page 2 hereof. Yes No

Listing of Inventors Continued from Page 1 of Declaration and Power of Attorney for invention entitled:

FULL NAME OF THIRD JOINT INVENTOR, IF ANY TOKUMOTO, Seiji	INVENTOR'S SIGNATURE <i>Seiji Tokumoto</i>	DATE Aug. 17. 2004
RESIDENCE c/o Tsukuba Laboratory of Hisamitsu Pharmaceutical Co., Inc., 25-11, Kannondai 1-chome, Tsukuba-shi, Ibaraki 305-0856 JAPAN	CITIZENSHIP JAPANESE	
POST OFFICE ADDRESS		
FULL NAME OF FOURTH JOINT INVENTOR, IF ANY SATO, Shuji	INVENTOR'S SIGNATURE <i>Shuji Sato</i>	DATE Aug. 17. 2004
RESIDENCE Greenhaws A-104, 1-11-5, Arima, Miyamae-ku, Kawasaki-shi, Kanagawa 216-0003 JAPAN	CITIZENSHIP JAPANESE	
POST OFFICE ADDRESS		
FULL NAME OF FIFTH JOINT INVENTOR, IF ANY SUGIBAYASHI, Kenji	INVENTOR'S SIGNATURE <i>Kenji Sugibayashi</i>	DATE Aug. 23. 2004
RESIDENCE 14-46, Arajyuku-machi 1-chome, Kawagoe-shi, Saitama 350-1124 JAPAN	CITIZENSHIP JAPANESE	
POST OFFICE ADDRESS		
FULL NAME OF SIXTH JOINT INVENTOR, IF ANY	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		
FULL NAME OF SEVENTH JOINT INVENTOR, IF ANY	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		
FULL NAME OF EIGHTH JOINT INVENTOR, IF ANY	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		
FULL NAME OF NINTH JOINT INVENTOR, IF ANY	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		
FULL NAME OF TENTH JOINT INVENTOR, IF ANY	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		

SPECIFICATION

INSULIN-ADMINISTERING DEVICE

Technical Field

The present invention relates to an insulin-administering device for percutaneously or transmucosally administering a lispro, using power of electric fields.

Background Art

Patients with diabetes are broadly classified into patients with type II diabetes, who can be treated with oral antidiabetics such as sulfonylurea, and patients with type I diabetes, who secrete no insulin. Since patients with type I diabetes secrete no insulin, they require administration of insulin. Even in the case of patients with type II diabetes, when it is difficult for them to control blood glucose, a therapeutic method for administering insulin is applied, as in the case of patients with type I diabetes. However, while insulin has high blood glucose-controlling effects, it is poor in absorptivity and stability. Thus, insulin cannot be orally administered. In addition, insulin has low sustainability. Under the current circumstances, insulin is administered by injection on a frequent basis from one to several times a day. However, such injection involves certain amount of pain. International Publication WO02/02179A1 describes an example of percutaneously